Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
European Urology Focus|July 23, 2026
Dose-intensified PSMA Radioligand Therapy: The Rationale Behind the OPTIMAL-PSMA TrialGemma Sheehan-Dare, Sobia Khan, Louise EmmettJournal of Medical Imaging and Radiation Oncology|September 15, 2021
Prostate adenocarcinoma with mucinous features - is it PSMA avid?Patrick J Horsley, Gemma Sheehan-Dare, Katerina Mastrocostas, et al.Pharmaceuticals (Basel, Switzerland)|July 27, 2022
64Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I TrialKeith Wong, Gemma Sheehan-Dare, Andrew Nguyen, et al.Journal of Medical Imaging and Radiation Oncology|October 22, 2021
Diagnostic value of 68 Ga-DOTATATE PET-CT imaging for staging of ER+ /PR+ HER2- breast cancer patients with metastatic disease: Comparison with conventional imaging with bone scan, diagnostic CT and 18 F-FDG PET-CT in a prospective pilot trialAndrew Nguyen, Karen Fullard, Gemma Sheehan-Dare, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 18, 2022
The PRIMARY Score: Using Intraprostatic 68Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer DiagnosisLouise Emmett, Nathan Papa, James Buteau, et al.BJU International|November 13, 2022
Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancerPaul Doan, William Counter, Nathan Papa, et al.European Urology|September 1, 2021
The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre StudyLouise Emmett, James Buteau, Nathan Papa, et al.Pageof 1